Mologni L - Search Results

1

Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.

Fontana D, Malighetti F, Villa M, Zambon A, Gambacorti-Passerini C, Mologni L. Fontana D, et al. Among authors: mologni l. Leukemia. 2024 Aug;38(8):1843-1847. doi: 10.1038/s41375-024-02282-y. Epub 2024 May 15. Leukemia. 2024. PMID: 38750137 Free PMC article. No abstract available.

2

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.

le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C. le Coutre P, et al. Among authors: mologni l. J Natl Cancer Inst. 1999 Jan 20;91(2):163-8. doi: 10.1093/jnci/91.2.163. J Natl Cancer Inst. 1999. PMID: 9923858

3

In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid.

Mologni L, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Biochem Biophys Res Commun. 1999 Oct 22;264(2):537-43. doi: 10.1006/bbrc.1999.1548. Biochem Biophys Res Commun. 1999. PMID: 10529398

4

Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-alpha and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid.

Mologni L, Marchesi E, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Cancer Res. 2001 Jul 15;61(14):5468-73. Cancer Res. 2001. PMID: 11454693

5

Expression, purification, and inhibition of human RET tyrosine kinase.

Mologni L, Sala E, Riva B, Cesaro L, Cazzaniga S, Redaelli S, Marin O, Pasquato N, Donella-Deana A, Gambacorti-Passerini C. Mologni L, et al. Protein Expr Purif. 2005 May;41(1):177-85. doi: 10.1016/j.pep.2005.01.002. Protein Expr Purif. 2005. PMID: 15802236

6

A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.

Sala E, Mologni L, Cazzaniga S, Papinutto E, Gambacorti-Passerini C. Sala E, et al. Among authors: mologni l. Int J Biol Macromol. 2006 Aug 15;39(1-3):60-5. doi: 10.1016/j.ijbiomac.2006.01.006. Epub 2006 Feb 21. Int J Biol Macromol. 2006. PMID: 16490247

7

Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.

Gunby RH, Ahmed S, Sottocornola R, Gasser M, Redaelli S, Mologni L, Tartari CJ, Belloni V, Gambacorti-Passerini C, Scapozza L. Gunby RH, et al. Among authors: mologni l. J Med Chem. 2006 Sep 21;49(19):5759-68. doi: 10.1021/jm060380k. J Med Chem. 2006. PMID: 16970400

8

Inhibition of RET tyrosine kinase by SU5416.

Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, Bain J, Cleris L, Redaelli S, Riva B, Formelli F, Scapozza L, Gambacorti-Passerini C. Mologni L, et al. J Mol Endocrinol. 2006 Oct;37(2):199-212. doi: 10.1677/jme.1.01999. J Mol Endocrinol. 2006. PMID: 17032739

9

Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.

Coluccia AM, Vacca A, Duñach M, Mologni L, Redaelli S, Bustos VH, Benati D, Pinna LA, Gambacorti-Passerini C. Coluccia AM, et al. Among authors: mologni l. EMBO J. 2007 Mar 7;26(5):1456-66. doi: 10.1038/sj.emboj.7601485. Epub 2007 Feb 22. EMBO J. 2007. PMID: 17318191 Free PMC article.

10

Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy.

Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L. Gunby RH, et al. Among authors: mologni l. Anticancer Agents Med Chem. 2007 Nov;7(6):594-611. doi: 10.2174/187152007784111340. Anticancer Agents Med Chem. 2007. PMID: 18045055 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters